Literature DB >> 29411231

Analysis of Chronic Granulomatous Disease in the Kavkazi Population in Israel Reveals Phenotypic Heterogeneity in Patients with the Same NCF1 mutation (c.579G>A).

Baruch Wolach1,2, Ronit Gavrieli3,4, Martin de Boer5, Karin van Leeuwen5, Ofir Wolach6, Galia Grisaru-Soen7, Arnon Broides8,9, Amos Etzioni10, Raz Somech3,11, Dirk Roos5.   

Abstract

PURPOSE: Chronic granulomatous disease (CGD) is an innate immune deficiency disorder of phagocytes, resulting from mutations in the components of the NADPH oxidase complex that impair the synthesis of oxygen radicals, thus rendering patients susceptible to recurrent infections and excessive hyperinflammatory responses. The most common autosomal recessive form of CGD is p47phox deficiency, which is often clinically milder than the more common X-linked recessive form. Here, we report data on genetics, clinical and biochemical findings in 17 CGD patients of Kavkazi origin with the nonsense mutation c.579G>A in the NCF1 gene, leading to p47phox deficiency.
METHODS: Diagnosis was based on detailed clinical evaluation, respiratory burst activity by cytochrome c reduction and dihydrorhodamine-1,2,3 (DHR) assay by flow cytometry, expression of p47phox by immunoblotting and molecular confirmation by DNA sequence analysis.
RESULTS: Twelve male and five female patients with median age at onset of 2.5 years (range 1 day to 9 years) were included in the study. The present cohort displays an encouraging 88% overall long-term survival, with median follow-up of 17 years. Clinical manifestations varied from mild to severe expression of the disease. Correlation between genotype and phenotype is unpredictable, although the Kavkazi patients were more severely affected than other patients with p47phox deficiency.
CONCLUSIONS: Kavkazi CGD patients harbor a common genetic mutation that is associated with a heterogeneous clinical phenotype. Early diagnosis and proper clinical management in an experienced phagocytic leukocyte center is imperative to ensure favorable patient outcome. New treatment strategies are ongoing, but results are not yet conclusive.

Entities:  

Keywords:  Bone marrow transplantation; NADPH-oxidase subunits; chronic granulomatous disease; hyperinflammatory states; neutrophil function; reactive oxygen species; recurrent pyogenic infections

Mesh:

Substances:

Year:  2018        PMID: 29411231     DOI: 10.1007/s10875-018-0475-1

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  42 in total

1.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

2.  Lessons learned from phagocytic function studies in a large cohort of patients with recurrent infections.

Authors:  Baruch Wolach; Ronit Gavrieli; Dirk Roos; Sivan Berger-Achituv
Journal:  J Clin Immunol       Date:  2011-12-30       Impact factor: 8.317

3.  Common severe infections in chronic granulomatous disease.

Authors:  Beatriz E Marciano; Christine Spalding; Alan Fitzgerald; Daphne Mann; Thomas Brown; Sharon Osgood; Lynne Yockey; Dirk N Darnell; Lisa Barnhart; Janine Daub; Lisa Boris; Amy P Rump; Victoria L Anderson; Carissa Haney; Douglas B Kuhns; Sergio D Rosenzweig; Corin Kelly; Adrian Zelazny; Tamika Mason; Suk See DeRavin; Elizabeth Kang; John I Gallin; Harry L Malech; Kenneth N Olivier; Gulbu Uzel; Alexandra F Freeman; Theo Heller; Christa S Zerbe; Steven M Holland
Journal:  Clin Infect Dis       Date:  2014-12-23       Impact factor: 9.079

4.  Enhanced inflammatory responses of chronic granulomatous disease leukocytes involve ROS-independent activation of NF-kappa B.

Authors:  Johan Bylund; Kelly L MacDonald; Kelly L Brown; Piotr Mydel; L Vincent Collins; Robert E W Hancock; David P Speert
Journal:  Eur J Immunol       Date:  2007-04       Impact factor: 5.532

Review 5.  Infections associated with chronic granulomatous disease: linking genetics to phenotypic expression.

Authors:  Josef Ben-Ari; Ofir Wolach; Ronit Gavrieli; Baruch Wolach
Journal:  Expert Rev Anti Infect Ther       Date:  2012-08       Impact factor: 5.091

6.  A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity.

Authors:  Juan D Matute; Andres A Arias; Nicola A M Wright; Iwona Wrobel; Christopher C M Waterhouse; Xing Jun Li; Christophe C Marchal; Natalie D Stull; David B Lewis; MacGregor Steele; James D Kellner; Weiming Yu; Samy O Meroueh; William M Nauseef; Mary C Dinauer
Journal:  Blood       Date:  2009-08-19       Impact factor: 22.113

7.  Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study.

Authors:  Baldassarre Martire; Roberto Rondelli; Annarosa Soresina; Claudio Pignata; Teresa Broccoletti; Andrea Finocchi; Paolo Rossi; Marco Gattorno; Marco Rabusin; Chiara Azzari; Rosa M Dellepiane; Maria C Pietrogrande; Antonino Trizzino; Paolo Di Bartolomeo; Silvana Martino; Luigi Carpino; Fausto Cossu; Franco Locatelli; Rita Maccario; Paolo Pierani; Maria C Putti; Achille Stabile; Luigi D Notarangelo; Alberto G Ugazio; Alessandro Plebani; Domenico De Mattia
Journal:  Clin Immunol       Date:  2007-11-26       Impact factor: 3.969

8.  Clinical, functional, and genetic characterization of chronic granulomatous disease in 89 Turkish patients.

Authors:  Mustafa Yavuz Köker; Yıldız Camcıoğlu; Karin van Leeuwen; Sara Şebnem Kılıç; Işıl Barlan; Mustafa Yılmaz; Ayşe Metin; Martin de Boer; Hüseyin Avcılar; Türkan Patıroğlu; Alişan Yıldıran; Olcay Yeğin; Ilhan Tezcan; Özden Sanal; Dirk Roos
Journal:  J Allergy Clin Immunol       Date:  2013-07-31       Impact factor: 10.793

Review 9.  Neutrophils: Between host defence, immune modulation, and tissue injury.

Authors:  Philipp Kruger; Mona Saffarzadeh; Alexander N R Weber; Nikolaus Rieber; Markus Radsak; Horst von Bernuth; Charaf Benarafa; Dirk Roos; Julia Skokowa; Dominik Hartl
Journal:  PLoS Pathog       Date:  2015-03-12       Impact factor: 6.823

10.  Pioglitazone as a novel therapeutic approach in chronic granulomatous disease.

Authors:  Maddalena Migliavacca; Andrea Assanelli; Francesca Ferrua; Maria Pia Cicalese; Alessandra Biffi; Marta Frittoli; Paolo Silvani; Giovanna Chidini; Edoardo Calderini; Anna Mandelli; Anna Camporesi; Raffaella Milani; Giada Farinelli; Roberto Nicoletti; Fabio Ciceri; Alessandro Aiuti; Maria Ester Bernardo
Journal:  J Allergy Clin Immunol       Date:  2016-04-04       Impact factor: 10.793

View more
  1 in total

1.  Second Report of Chronic Granulomatous Disease in Jordan: Clinical and Genetic Description of 31 Patients From 21 Different Families, Including Families From Lybia and Iraq.

Authors:  Faris Ghalib Bakri; Michelle Mollin; Sylvain Beaumel; Bénédicte Vigne; Nathalie Roux-Buisson; Adel Mohammed Al-Wahadneh; Raed Mohammed Alzyoud; Wail Ahmad Hayajneh; Ammar Khaled Daoud; Mohammed Elian Abu Shukair; Mansour Fuad Karadshe; Mahmoud Mohammad Sarhan; Jamal Ahmad Wadi Al-Ramahi; Julien Fauré; John Rendu; Marie Jose Stasia
Journal:  Front Immunol       Date:  2021-03-05       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.